| Followers | 375 |
| Posts | 16963 |
| Boards Moderated | 4 |
| Alias Born | 03/07/2014 |
Friday, September 18, 2015 12:28:01 PM
2nd quarter ENDED on June 30th 2015, and NO, IT DID NOT REACH $35.00 a share, LOL !!!
The 3rd quarter is ENDING in a few weeks, end of Sept 2015 and NO, NO IT'S NOT going to be "$70.00 a share", LOL !!!!!!!!
AND NO, none of the other vast "predictions" from that ole micro site stem cell blog thingy have YET TO COME TRUE EITHER, LOL !!!
Quote (MASSIVE BS, LOL !!!):
"
"Post from a OCAT board.
OCATA Therapeutics PPS projections based on TOTAL ADDRESSABLE MARKET(TAM) for Pivotal SMD and Phase 2 AMD and upcoming milestones 2015/2016
2nd quarter 2015: $35.00 plus (NO, DID NOT HAPPEN, LOL !!)
Based on upcoming OCAT Milestones in Q2:
1. SMD granted SPA by USFDA. (BIG NO on that one too)
2. First SMD patient treated in Pivotal Trial. (Uh, NO)
3. First AMD patient treated in phase 2 Trial. (Uh, NO)
4. Asian patients Data published. (I think that's a big NO too?)
5. Phase 1 complete data set released of all 38 patient AMD trial. (NO too, pretty sure?????)
6. JV Non core assets. ( A giant NO, LOL !!!!)
7. Data published for Tuft's dog trials based on OCAT cell therapies for Lupus, Chron's etc. (Pretty sure that was a big ole Q-2, NO too?)
8. IND filed with FDA for RPC's to cure blindness even in patients with dead rods and cones. (Also a NO, pretty sure in Q-2?)
9. Multiple additional sites for both here and EU for both SMD and AMD trials. (AND a giant NO in Q-2 LOL !!!)
3rd quarter 2015: $70.00 plus (Uh, HUGE NO, LOL !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!)
1. EU Pivotal Trial SMD Therapy partnership with major EU Big PHARMA. (And a monumental NO on that one too, unless a miracle happens in 2 weeks, LOL !!!!! Too date, ONE PATIENT is "enrolled" LOL and Q3 is ENDING)
2. US partnership for AMD therapy. (NO, NO and NO on that one too looks like to me, LOL!!)
3. MS mice data published in peer review Journal. (Pretty sure that's a NO TOO?????)
4th quarter 2015: $ 100.00+ (I'm gonna go with a MEGA NO on that one, LOL !!!!!!!!!!!!!!!!!!!!!!!!! Like a totally NO !!!!)
1. EU halts orphan SMD pivotal trial and grants OCAT marketing authorization for all of EU based on overwhelming safety and efficacy. (Also going with a NO on that one too IMO)
2. US FDA halts orphan SPA SMD therapy and grants approval based on overwhelming safety and efficacy.)
3. FDA grants breakthrough designation for OCAT AMD therapy. (A GIANT NO on that one too IMO)
4. Dr. Lanza and Dr. Langer receive Nobel. (And a BIG OLE NO IMO on that one too, LOL !!!!) "
"
LOL !!!!!!!!!!!!!!
Getting close to that time of day when it should SELL OFF more than likely and give up this blip of a micro-gain today. Else, it will sell-off on Monday more than likely- giving it all back to the $4.50 a share, not a Big Mac meal range as usual IMO. $5 is a brick wall right now- and it's needs $6 to $7 just to get to BREAK EVEN where it was even a few months ago.
The 3rd quarter is ENDING in a few weeks, end of Sept 2015 and NO, NO IT'S NOT going to be "$70.00 a share", LOL !!!!!!!!
AND NO, none of the other vast "predictions" from that ole micro site stem cell blog thingy have YET TO COME TRUE EITHER, LOL !!!
Quote (MASSIVE BS, LOL !!!):
"
"Post from a OCAT board.
OCATA Therapeutics PPS projections based on TOTAL ADDRESSABLE MARKET(TAM) for Pivotal SMD and Phase 2 AMD and upcoming milestones 2015/2016
2nd quarter 2015: $35.00 plus (NO, DID NOT HAPPEN, LOL !!)
Based on upcoming OCAT Milestones in Q2:
1. SMD granted SPA by USFDA. (BIG NO on that one too)
2. First SMD patient treated in Pivotal Trial. (Uh, NO)
3. First AMD patient treated in phase 2 Trial. (Uh, NO)
4. Asian patients Data published. (I think that's a big NO too?)
5. Phase 1 complete data set released of all 38 patient AMD trial. (NO too, pretty sure?????)
6. JV Non core assets. ( A giant NO, LOL !!!!)
7. Data published for Tuft's dog trials based on OCAT cell therapies for Lupus, Chron's etc. (Pretty sure that was a big ole Q-2, NO too?)
8. IND filed with FDA for RPC's to cure blindness even in patients with dead rods and cones. (Also a NO, pretty sure in Q-2?)
9. Multiple additional sites for both here and EU for both SMD and AMD trials. (AND a giant NO in Q-2 LOL !!!)
3rd quarter 2015: $70.00 plus (Uh, HUGE NO, LOL !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!)
1. EU Pivotal Trial SMD Therapy partnership with major EU Big PHARMA. (And a monumental NO on that one too, unless a miracle happens in 2 weeks, LOL !!!!! Too date, ONE PATIENT is "enrolled" LOL and Q3 is ENDING)
2. US partnership for AMD therapy. (NO, NO and NO on that one too looks like to me, LOL!!)
3. MS mice data published in peer review Journal. (Pretty sure that's a NO TOO?????)
4th quarter 2015: $ 100.00+ (I'm gonna go with a MEGA NO on that one, LOL !!!!!!!!!!!!!!!!!!!!!!!!! Like a totally NO !!!!)
1. EU halts orphan SMD pivotal trial and grants OCAT marketing authorization for all of EU based on overwhelming safety and efficacy. (Also going with a NO on that one too IMO)
2. US FDA halts orphan SPA SMD therapy and grants approval based on overwhelming safety and efficacy.
3. FDA grants breakthrough designation for OCAT AMD therapy. (A GIANT NO on that one too IMO)
4. Dr. Lanza and Dr. Langer receive Nobel. (And a BIG OLE NO IMO on that one too, LOL !!!!) "
"
LOL !!!!!!!!!!!!!!
Getting close to that time of day when it should SELL OFF more than likely and give up this blip of a micro-gain today. Else, it will sell-off on Monday more than likely- giving it all back to the $4.50 a share, not a Big Mac meal range as usual IMO. $5 is a brick wall right now- and it's needs $6 to $7 just to get to BREAK EVEN where it was even a few months ago.
Posts contain only my amateur opinions, personal views and thoughts. I discuss stocks as a hobby only. Always do one's own due diligence before investing.
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
